ストックスクリーナーアプリを入手
26.87
1.43%
0.28
前日終値:
$26.59
開ける：
$27.03
24時間の取引高:
32,492
Relative Volume:
0.14
時価総額：
$1.13B
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
+17.11%
1か月 パフォーマンス:
+33.32%
6か月 パフォーマンス:
+240.10%
1年 パフォーマンス:
+54.73%
1日の値動き範囲:
$26.05
$27.67
1週間の範囲:
$18.33
$29.73
52週間の値動き範囲:
$5.83
$29.73
Zenas Biopharma Inc Stock (ZBIO) Company Profile
名前
Zenas Biopharma Inc
セクター
電話
857-271-2954
住所
852 WINTER STREET, SUITE 250, WALTHAM
ZBIO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ZBIO
Zenas Biopharma Inc
|
26.74 | 1.25B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.75 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
461.73 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
550.86 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
800.40 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.15 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Zenas Biopharma Inc Stock (ZBIO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-20 | 開始されました | Wedbush | Outperform |
| 2025-02-04 | 開始されました | Wolfe Research | Outperform |
| 2024-12-16 | 開始されました | H.C. Wainwright | Buy |
| 2024-11-05 | 開始されました | Rodman & Renshaw | Buy |
| 2024-10-08 | 開始されました | Citigroup | Buy |
| 2024-10-08 | 開始されました | Guggenheim | Buy |
| 2024-10-08 | 開始されました | Jefferies | Buy |
| 2024-10-08 | 開始されました | Morgan Stanley | Overweight |
すべてを表示
Zenas Biopharma Inc (ZBIO) 最新ニュース
What to expect from Zenas BioPharma Inc. in the next 30 daysPortfolio Growth Summary & Long-Term Growth Stock Strategies - newser.com
How Zenas BioPharma Inc. stock reacts to inflationary pressuresMarket Trend Review & Low Drawdown Trading Techniques - newser.com
Zenas BioPharma, Inc. (ZBIO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Zenas BioPharma Independent Director Acquires 447% More Stock - simplywall.st
Zenas climbs on licensing deal with InnoCare - MSN
Zenas Biopharma stock hits all-time high at 29.29 USD By Investing.com - Investing.com Canada
Insider Buying: Zenas BioPharma (NASDAQ:ZBIO) Insider Buys 36,928 Shares of Stock - MarketBeat
Zenas BioPharma (NASDAQ:ZBIO) Director Hongbo Lu Purchases 263,160 Shares - MarketBeat
Fairmount Funds Management Llc Acquires 316,219 Shares of Zenas BioPharma (NASDAQ:ZBIO) Stock - MarketBeat
Zenas Biopharma stock hits all-time high at 29.29 USD - Investing.com India
Zenas BioPharma (ZBIO) Is Up 32.5% After Securing Global Rights to Orelabrutinib in MS Deal - Yahoo Finance
Zenas BioPharma (NASDAQ:ZBIO) Sets New 1-Year High Following Analyst Upgrade - MarketBeat
Zenas BioPharma Inc Stock Analysis and ForecastSector Rotation Strategies & Watch Expert Picks Before They Rally - earlytimes.in
Will Zenas BioPharma Inc. stock go up soonTrade Entry Summary & Scalable Portfolio Growth Ideas - newser.com
Wedbush Issues Positive Forecast for Zenas BioPharma (NASDAQ:ZBIO) Stock Price - MarketBeat
HC Wainwright Reiterates Buy Rating for Zenas BioPharma (NASDAQ:ZBIO) - MarketBeat
Zenas BioPharma files automatic mixed securities shelf - MSN
Zenas BioPharma: Strategic Licensing and Clinical Advancements Justify Buy Rating - TipRanks
Rx Rundown: Novo Nordisk, Chiesi Group, Zenas Biopharma and more - Medical Marketing and Media
Zenas Biopharma (ZBIO) director Moulder buys $770k in shares By Investing.com - Investing.com South Africa
InnoCare Pharma: Obutinib signs licensing agreement with Zenas BioPharma - iHeart
Insider Buying Spree: Zenas BioPharma Executives Make Bold Moves! - TipRanks
Zenas Biopharma (ZBIO) director Moulder buys $770k in shares - Investing.com India
Lu Hongbo buys Zenas Biopharma (ZBIO) shares worth $6m - Investing.com
Zenas BioPharma rises after Wedbush raises price target - MSN
Zenas BioPharma hits record high as brokerages raise PT - TradingView
Zenas acquires BTK inhibitor in Phase 3 trials for progressive MS - Multiple Sclerosis News Today
Zenas BioPharma: Two Late-Stage Catalysts And A $2B InnoCare Deal (ZBIO) - Seeking Alpha
H.C. Wainwright maintains Zenas Biopharma stock Buy rating on pipeline expansion - Investing.com Canada
Strategic Expansion and Financial Strength Bolster Zenas BioPharma’s Growth Potential: Buy Rating Reaffirmed - TipRanks
Wedbush Raises Price Target on Zenas BioPharma to $40 From $35, Keeps Outperform Rating - MarketScreener
Risk vs reward if holding onto Zenas BioPharma Inc.Earnings Risk Summary & Expert Curated Trade Ideas - newser.com
Should you wait for a breakout in Zenas BioPharma Inc.July 2025 Retail & Risk Adjusted Swing Trade Ideas - newser.com
Zenas BioPharma (Nasdaq:ZBIO) Secures License for Three Autoimmune Candidates Including Orelabrutinib - Kalkine Media
Why Zenas BioPharma (ZBIO) Jumped 17.1% After Announcing $200M Shelf Filing and Major License Talks - simplywall.st
Zenas BioPharma and InnoCare Pharma Announce License - GlobeNewswire
Zenas Biopharma Inc Files For Mixed Shelf- SEC Filing - TradingView
Zenas Looks To Target Progressive Multiple Sclerosis Via InnoCare Deal - insights.citeline.com
Zenas gets global rights for Innocare BTK inhibitor in $2B+ deal - BioWorld MedTech
Zenas Biopharma Raises $120 Million To Secure Global Rights To Multiple Sclerosis Drug - inkl
Zenas BioPharma (NASDAQ:ZBIO) Receives "Sell (D-)" Rating from Weiss Ratings - MarketBeat
Zenas Bio inks potential $2 billion licensing deal with China's InnoCare for autoimmune drug - Reuters
Zenas inks license agreement with InnoCare for 3 autoimmune programs - The Pharma Letter
Zenas looks to China to stock pipeline with 3 more immune drugs - BioPharma Dive
Zenas BioPharma (NASDAQ:ZBIO) Shares Gap UpWhat's Next? - MarketBeat
InnoCare Pharma's US Unit Grants Exclusive License of MS Drug to Zenas BioPharma - 富途牛牛
Zenas climbs on licensing deal with InnoCare (ZBIO:NASDAQ) - Seeking Alpha
Zenas Biopharma stock soars after securing rights to MS drug candidate - Investing.com Australia
Zenas BioPharma Secures Licensing Deal with InnoCare - TipRanks
Waltham company forges $2B deal for MS drug - The Business Journals
InnoCare Pharma says unit entered exclusive license agreement & subscription agreement with Zenas BioPharma - MarketScreener
Zenas Biopharma Inc (ZBIO) 財務データ
Zenas Biopharma Inc (ZBIO) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
Zenas Biopharma Inc (ZBIO) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Fairmount Funds Management LLC | Director |
Oct 07 '25 |
Buy |
19.00 |
316,219 |
6,008,161 |
2,209,025 |
| Lu Hongbo | Director |
Oct 07 '25 |
Buy |
19.00 |
263,160 |
5,000,040 |
321,983 |
| MOULDER LEON O JR | Chief Executive Officer |
Feb 18 '25 |
Buy |
6.67 |
25,000 |
166,750 |
266,155 |
| Xiao Ting | Director |
Feb 07 '25 |
Buy |
7.76 |
10,000 |
77,600 |
47,000 |
| MOULDER LEON O JR | Chief Executive Officer |
Dec 04 '24 |
Buy |
9.98 |
45,000 |
449,100 |
241,155 |
| MOULDER LEON O JR | Chief Executive Officer |
Dec 03 '24 |
Buy |
10.76 |
25,000 |
269,000 |
196,155 |
| MOULDER LEON O JR | Chief Executive Officer |
Nov 18 '24 |
Buy |
15.00 |
7,500 |
112,500 |
168,655 |
| MOULDER LEON O JR | Chief Executive Officer |
Nov 19 '24 |
Buy |
14.57 |
2,500 |
36,425 |
171,155 |
0.21%
2.95%
大文字化:
|
ボリューム (24 時間):